---
title: "Dermata Therapeutics | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280690141.md"
datetime: "2026-03-26T21:20:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280690141.md)
  - [en](https://longbridge.com/en/news/280690141.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280690141.md)
---

# Dermata Therapeutics | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -8.16.

EBIT: As of FY2025, the actual value is USD -7.989 M.

### Financial Performance Overview

#### Net Loss

For the year ended December 31, 2025, Dermata Therapeutics, Inc. reported a net loss of -$7.6 million, an improvement from the -$12.3 million net loss recorded in the year ended December 31, 2024 . As of December 31, 2025, the company’s accumulated deficit stood at -$73.2 million .

#### Operating Expenses

-   **Research and Development (R&D) Expenses**: R&D expenses decreased by -$5.3 million, from $8.2 million in 2024 to $2.9 million in 2025 . This decrease was primarily due to a -$5.1 million reduction in clinical expenses following the completion of the STAR-1 acne study, along with a -$0.1 million decrease in chemistry, manufacturing, and controls (CMC) and non-clinical expenses, and a -$0.1 million decrease in personnel expenses .
-   **Selling, General and Administrative (SG&A) Expenses**: SG&A expenses increased by $0.5 million, rising from $4.3 million in 2024 to $4.8 million in 2025 . This increase was mainly driven by $0.7 million in marketing expenses incurred in 2025, partially offset by a -$0.2 million decrease in personnel expenses .

#### Interest Income

Interest income remained consistent at approximately $0.2 million for both the years ended December 31, 2025, and 2024 .

#### Cash Flows

-   **Cash Used in Operating Activities**: Cash used in operating activities was -$7,757,559 for 2025, compared to -$11,162,948 for 2024 .
-   **Cash Provided by Financing Activities**: Cash provided by financing activities totaled $12,117,967 in 2025, up from $6,886,383 in 2024 .
-   **Increase (Decrease) in Cash and Cash Equivalents**: The company experienced an increase of $4,360,408 in cash and cash equivalents in 2025, contrasting with a decrease of -$4,276,565 in 2024 .

#### Liquidity and Capital Resources

As of December 31, 2025, cash and cash equivalents amounted to $7.5 million . Since inception, Dermata Therapeutics, Inc. has raised approximately $82.0 million in gross proceeds from debt and equity securities sales .

**Financing Activities in 2025:** The January 2025 PIPE Financing generated net proceeds of approximately $2.2 million . The March 2025 Warrant Inducement Financing generated net proceeds of $5.7 million . The December 2025 PIPE Financing generated net proceeds of approximately $3.8 million . In December 2025, the company sold 149,341 shares of common stock for net proceeds of approximately $0.4 million, with $1.4 million capacity remaining under the ATM Agreement . An additional 824,283 shares were sold under the ATM Agreement in January 2026, generating approximately $2.0 million in net proceeds and exhausting the remaining ATM capacity .

### Outlook / Guidance

Dermata Therapeutics, Inc. expects to incur continued significant operating losses and increased selling, general, and administrative expenses due to marketing and personnel efforts for upcoming product launches . The company anticipates R&D expenses will not materially increase, but it will require additional financing as existing cash is projected to fund activities only into the first quarter of 2027 . These factors raise substantial doubt about Dermata Therapeutics, Inc.’s ability to continue as a going concern .

### Related Stocks

- [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
- [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference | DERM Stock News](https://longbridge.com/en/news/286965311.md)
- [Dear Future SpaceX (SPCX) Stock Fans, Mark Your Calendars for June 12](https://longbridge.com/en/news/286809659.md)
- [12:46 ETSpring Cleaning Starts in the Garage: A Step-by-Step Cleanout Guide for Homeowners](https://longbridge.com/en/news/286946537.md)
- [Dead Continent Walking? 12 Charts That Scream “Avoid Europe”](https://longbridge.com/en/news/286749017.md)